html { overflow: visible; height: auto; } .MainNav_ItemWrapper:hover .Subnavigation_Wrapper, .MainNav_Item:focus + .Subnavigation_Wrapper { display: block; } .Header-FixedHeight .Dialoog, .Header-FixedHeight .Title_Wrapper, .Accordion_ContentContainer.Hidden { height: auto !important; visibility: visible; } .Dialoog_Step.Invisible, .Title_Wrapper.Invisible, main.Invisible, .js-GridItem { transform: none; opacity: 1; } .Dialoog_Form, .js-OptionsOpenBtn, .Image_Wrapper-Scaled, .Video_Wrapper-Scaled, img[data-src] { display: none; } .js-MasonryGrid { display: flex; flex-wrap: wrap; }

About Aurelius Therapeutics BV

Aurelius Therapeutics is bravely developing novel radioligand therapies (RLTs) comprising highly selective tumour-targeting molecules and potent tumour-killing radioisotopes. We are focused on areas of significant unmet need in oncology, particularly intractable solid tumours. Aurelius Therapeutics: Defend Patients, Defeat Cancer.

go to main content

Listen

- Pagina niet beschikbaar in Nederlands ( NL )
- Seite nicht verfügbar auf Deutsch ( DE )

Go to Radboudumc Radboudumc

Aurelius Therapeutics BV

Welcome to Radboudumc How can we help you?

I am looking for ...

Radboudumc and partners Spin-off companies Aurelius Therapeutics BV

About Aurelius Therapeutics BV

Aurelius Therapeutics is bravely developing novel radioligand therapies (RLTs) comprising highly selective tumour-targeting molecules and potent tumour-killing radioisotopes.

Affiliated department: Radiology and Nuclear medicine and Organic chemistry (RU)
Researchers; Sandra Heskamp & James Nagarajah, Yvonne Derks and Dennis Löwik (RU)
Year of incorporation: 2024

What we do

spin-off companies

contact

Employees
mijnRadboud

About Aurelius Therapeutics BV

About Aurelius Therapeutics BV

Aurelius Therapeutics BV details

What we do